Anesth Pain Med.  2012 Oct;7(4):338-342.

The neuroprotective effect of colloids in forebrain ischemia model

Affiliations
  • 1Department of Anesthesiology and Pain Medicine, Seoul National University Bundang Hospital, Seongnam, Korea. ytjeon@snubh.org
  • 2Department of Anesthesiology and Pain Medicine, Seoul National University Hospital, Seoul, Korea.

Abstract

BACKGROUND
The aim of this study was to investigate the neuroprotective effects of colloids (albumin and pentastarch) after forebrain global ischemia in rats.
METHODS
Thirty male Sprague-Dawley rats were randomly assigned to three groups; control, albumin and pentastarch group (each n = 10). Forebrain ischemia was induced by bilateral common carotid artery occlusion plus hemorrhagic hypotension. The control group received no treatment. The albumin group received 5 ml/kg of 20% albumin after ischemia. The pentastarch group received same volume of albumin after ischemia. Histologic outcomes were measured at 7 days after ischemia in CA1 pyramidal cells of the rat hippocampus.
RESULTS
The mean percentage of viable cells in the hippocampal CA1 area was significantly higher in the albumin (47%) compared with the control group (33%) or pentastarch group (33%) (P = 0.001). The percentage of apoptotic cells was significantly lower in the albumin (30%) group than that in the pentastarch (44%) or control group (49%) (P = 0.006).
CONCLUSIONS
This study shows that albumin can improve histologic outcomes after forebrain global ischemia compared with pentastarch.

Keyword

Albumin; Brain ischemia; Hippocampus; Pentastarch

MeSH Terms

Animals
Brain Ischemia
Carotid Artery, Common
Colloids
Hetastarch
Hippocampus
Humans
Hypotension
Ischemia
Male
Neuroprotective Agents
Prosencephalon
Pyramidal Cells
Rats
Rats, Sprague-Dawley
Colloids
Hetastarch
Neuroprotective Agents
Full Text Links
  • APM
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr